

=&gt; d his

(FILE 'HOME' ENTERED AT 15:28:46 ON 23 JUN 2005)

L1 FILE 'HCAPLUS' ENTERED AT 15:31:45 ON 23 JUN 2005  
1 (GB99-17793 OR WO2000-GB2903#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 15:31:59 ON 23 JUN 2005

L2 FILE 'HCAPLUS' ENTERED AT 15:32:00 ON 23 JUN 2005  
TRA L1 1- RN : 65 TERMS

L3 FILE 'REGISTRY' ENTERED AT 15:32:00 ON 23 JUN 2005  
65 SEA L2

L4 FILE 'WPIX' ENTERED AT 15:32:02 ON 23 JUN 2005  
1 (GB99-17793 OR WO2000-GB2903#)/AP,PRN

=&gt; b hcap

FILE 'HCAPLUS' ENTERED AT 15:32:43 ON 23 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jun 2005 VOL 142 ISS 26  
FILE LAST UPDATED: 22 Jun 2005 (20050622/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; d all l1

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2001:101167 HCAPLUS  
DN 134:168315  
ED Entered STN: 09 Feb 2001  
TI Enhancement of bioavailability of peptides with bile salts  
IN Morrison, James Duncan; Lucas, Michael Leslie; Wheeler, Sarah  
PA The University Court of the University of Glasgow, UK  
SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM C07J  
CC 63-5 (Pharmaceuticals)  
Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009163	A2	20010208	WO 2000-GB2903	20000728 <--
	WO 2001009163	A3	20010907		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

Search done by Noble Jarrell

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 GB 2355009 A1 20010411 GB 1999-17793 19990730 <--  
 AU 2000061739 A5 20010219 AU 2000-61739 20000728 <--  
 EP 1228093 A2 20020807 EP 2000-948177 20000728 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 PRAI GB 1999-17793 A 19990730 <--  
 WO 2000-GB2903 W 20000728 <--

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001009163	ICM	C07J
WO 2001009163	ECLA	A61K047/48H4; C07K014/47; C07K014/575; C07K014/595 <--
GB 2355009	ECLA	A61K047/48H4; C07K014/47; C07K014/575; C07K014/595 <--
OS	MARPAT	134:168315
AB	The present invention relates to improving and/or increasing the bioavailability of a biol. active substance, such as a peptide. In particular the present invention relates to the conjugation of the biol. active substance to a bile acid. The conjugated biol. active substance is suitable particularly for oral or parental administration. Ileal administration of 600µg/kg gastrin tetrapeptide conjugated to cholate resulted in a significant mean increase in gastric acid secretion of 1.84 µmol over a 3 h collection period, while no increase in acid secretion was noticed by administration of tetragastrin alone or with sep. cholate.	
ST	bioavailability enhancement peptide bile salt	
IT	Immunoglobulins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (A; enhancement of bioavailability of peptides with bile salts)	
IT	Immunoglobulins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (D; enhancement of bioavailability of peptides with bile salts)	
IT	Immunoglobulins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (E; enhancement of bioavailability of peptides with bile salts)	
IT	Immunoglobulins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (G; enhancement of bioavailability of peptides with bile salts)	
IT	Immunoglobulins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (M; enhancement of bioavailability of peptides with bile salts)	
IT	Chemotherapy (agents; enhancement of bioavailability of peptides with bile salts)	
IT	Adrenoceptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; enhancement of bioavailability of peptides with bile salts)	
IT	Anemia (disease) (antianemic factors; enhancement of bioavailability of peptides with bile salts)	
IT	Peptides, biological studies	

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(conjugates; enhancement of bioavailability of peptides with bile salts)

- IT Adrenoceptor agonists
- Adrenoceptor antagonists
- Analgesics
- Anesthetics
- Anti-inflammatory agents
- Antianginal agents
- Antiarrhythmics
- Antibacterial agents
- Anticoagulants
- Anticonvulsants
- Antidepressants
- Antihistamines
- Antiparkinsonian agents
- Antipsychotics
- Antiviral agents
- Anxiolytics
- Cardiotonics
- Diuretics
- Drug bioavailability
- Fungicides
- Hypnotics and Sedatives
- Hypolipemic agents
- Muscarinic agonists
- Muscarinic antagonists
- Nicotinic antagonists
- Parasitocides
- Permeation enhancers
- Stomach
- Vasodilators
- (enhancement of bioavailability of peptides with bile salts)
- IT Peptides, biological studies
- RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT Antibodies
- Blood-coagulation factors
- Ferritins
- Glycoproteins, general, biological studies
- Hemoglobins
- Interferons
- Oligonucleotides
- Opioids
- Polynucleotides
- Polysaccharides, biological studies
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT Bile acids
- RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT Bile salts
- RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT Gastrointestinal motility
- (gastric, drugs for treatment of; enhancement of bioavailability of peptides with bile salts)

- IT Drug delivery systems  
(oral; enhancement of bioavailability of peptides with bile salts)
- IT Drug delivery systems  
(parenterals; enhancement of bioavailability of peptides with bile salts)
- IT Antiulcer agents  
(peptic; enhancement of bioavailability of peptides with bile salts)
- IT Neuropeptides  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(transmitters; enhancement of bioavailability of peptides with bile salts)
- IT 9001-08-5D, inhibitor  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anticholinesterase; enhancement of bioavailability of peptides with bile salts)
- IT 50-56-6, Oxytocin, biological studies 1393-25-5, Secretin 8001-27-2, Hirudin 9001-05-2, Catalase 9001-27-8, Factor viii 9001-28-9, Factor IX 9002-60-2, Acth, biological studies 9002-61-3, Chorionic gonadotropin 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Somatotropin 9002-76-0, Gastrin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9007-43-6, Cytochrome c, biological studies 9007-92-5, Glucagon, biological studies 9011-97-6, Cholecystokinin 9015-71-8, Corticotropin releasing hormone 9015-94-5, Renin, biological studies 9034-39-3, Growth hormone releasing hormone 9034-40-6, Gonadotropin releasing hormone 9038-70-4, Somatomedin 9039-53-6, Urokinase 9041-90-1, Angiotensin I 9054-89-1, Superoxide dismutase 9087-70-1, Aprotinin 11000-17-2, Antidiuretic hormone 11096-26-7, Erythropoietin 11128-99-7, Angiotensin II 24305-27-9, Thyrotropin releasing hormone 51110-01-1, Somatostatin 57285-09-3, Inhibin 59392-49-3, Gastric inhibitory peptide 67763-96-6, Igf1 67763-97-7, Igf2 80043-53-4, Gastrinreleasing peptide 85637-73-6, Atrial natriuretic hormone 89750-14-1, Glucagon-like peptide I 119418-04-1, Galanin 139639-23-9, Tissue plasminogen activator  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT 79-14-1D, Glycolic acid, salts 81-24-3D, Taurocholic acid, salts 81-25-4, Cholic acid 83-44-3D, Deoxycholic acid, salts 128-13-2D, Ursodeoxycholic acid, salts 360-65-6D, Glycodeoxycholic acid, salts 474-25-9D, Chenodeoxycholic acid, salts 474-74-8D, Glycolithocholic acid, salts 516-35-8D, Taurochenodeoxycholic acid, salts 516-50-7D, Taurodeoxycholic acid, salts 516-90-5D, TAurolithocholic acid, salts 640-79-9D, Glycochenodeoxycholic acid, salts 14605-22-2D, Tauroursodeoxycholic acid, salts 63948-32-3 64480-66-6D, Glycoursodeoxycholic acid, salts 83381-47-9, Gastrin-34 I (rat) 171511-54-9 324753-46-0 325142-35-6  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(enhancement of bioavailability of peptides with bile salts)
- IT 9003-99-0, Peroxidase  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(horseradish; enhancement of bioavailability of peptides with bile salts)
- IT 9002-10-2, Tyrosinase  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mushroom; enhancement of bioavailability of peptides with bile salts)  
 IT 9035-81-8, Trypsin inhibitor  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (soy bean; enhancement of bioavailability of peptides with bile salts)

=> b wpix

FILE 'WPIX' ENTERED AT 15:32:54 ON 23 JUN 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 21 JUN 2005 <20050621/UP>  
 MOST RECENT DERWENT UPDATE: 200539 <200539/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
 FIRST VIEW - FILE WPIFV.  
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
 PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-revision/>  
 FOR DETAILS. <<<

=> d all 14 tot

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2001-182932 [18] WPIX  
 DNC C2001-054613  
 TI Novel amide of bile salt which is conjugated to a biologically active  
 substance useful for improving and/or increasing bioavailability of  
 biologically active substance when administered orally or parenterally.  
 DC B04  
 IN LUCAS, M L; MORRISON, J D; WHEELER, S  
 PA (UNIU) UNIV GLASGOW; (LUCA-I) LUCAS M L; (MORR-I) MORRISON J D; (WHEE-I)  
 WHEELER S  
 CYC 95  
 PI WO 2001009163 A2 20010208 (200118)\* EN 28 C07J000-00  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 GB 2355009 A 20010411 (200122) C07K017-00  
 AU 2000061739 A 20010219 (200129) C07J000-00  
 EP 1228093 A2 20020807 (200259) EN C07K014-595  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 ADT WO 2001009163 A2 WO 2000-GB2903 20000728; GB 2355009 A GB  
 1999-17793 19990730; AU 2000061739 A AU 2000-61739 20000728; EP  
 1228093 A2 EP 2000-948177 20000728, WO 2000-GB2903 20000728

FDT AU 2000061739 A Based on WO 2001009163; EP 1228093 A2 Based on WO 2001009163

PRAI GB 1999-17793 19990730

IC ICM C07J000-00; C07K014-595; C07K017-00

ICS A61K038-04; A61K047-28; A61K047-48; C07K014-47; C07K014-575

AB WO 200109163 A UPAB: 20010402

NOVELTY - An amide of a bile acid/salt bonded by an amide bond to a peptide (I), is new.

DETAILED DESCRIPTION - An amide of a bile acid/salt bonded by an amide bond to a peptide of formula -X-Y (I), is new.

X = a peptide chain of at least four amino acids in length or comprise two or more cross-linked polypeptide chains; and

Y = OH, NH<sub>2</sub>, or a 1-6C ester group bonded to the terminal carboxy of the polypeptide chain.

INDEPENDENT CLAIMS are also included for:

(1) preparation of a pharmaceutical formulation involves bringing into association (I) and a carrier; and

(2) use of an amide of a bile acid/salt compound of formula (III) in the manufacture of a medicament suitable for parenteral administration.

R<sub>1</sub>-R<sub>5</sub> = OH, H or 1-6C alkyl;

B' = -R<sub>6</sub>-CO-Z;

R<sub>6</sub> = 2-6C alkylene; and

Z = a pharmaceutically active agent.

ACTIVITY - Anesthetic; tranquilizer; hypnotic; neuroleptic; antidepressant; anticonvulsant; antiparkinsonian; analgesic; neuroprotective; vasodilator; antianginal; cardiant; anticoagulant; antilipemic; antiinflammatory; antiulcer; bactericidal; virucidal; fungicidal; parasiticidal; antianemic.

MECHANISM OF ACTION - None given.

USE - (I) is useful for therapy and is useful in the manufacture of a medicament in a form suitable for oral administration.

ADVANTAGE - Conjugation of a pharmaceutically active substance to the bile acid via the carboxylic acid group of the bile acid results in improved uptake of the active substance into the blood stream when administered orally. The conjugated compound may also be administered parenterally at much lower doses than unconjugated form of the biologically active substance. The pharmacokinetics and/or bioavailability of a biologically active material are improved when a bile salt or acid-conjugated biologically active material is administered parenterally.

Experiments were carried out on male Wistar rats. After anesthetization the surgical procedures were carried out to allow incubation of the stomach at the pyloroduodenal junction after ligation of the esophagus to measure gastric acid secretion, cannulation of the terminal ileum and/or of the proximal jejunum distal to the ligament of Treitz for infusion of peptide hormones. Gastric acid secretion was measure by the following method. Gastrin tetrapeptide (G4) (Trp-Met-Asp-Phe amide) and cholate-Trp-Met-Asp-Phe amide conjugate (G4-CA), was used as the test substance. Experiments with gastrin tetrapeptide (G4) showed that biologically active G4 was not absorbed across the wall of the small intestine. In 6 experiments, ileal infusion of a large dose of G4 (2500 micro g kg<sup>-1</sup> in 1.0 ml isotonic saline) actually resulted in a fall in the mean gastric acid level of 0.23 plus or minus 0.21 micro mol hr<sup>-1</sup>. Thus, it was demonstrated that G4 was not absorbed across the wall of the ileum. This lack of absorption of G4 was also confirmed for the upper jejunum. It was also to test whether G4-CA was absorbed from the small intestine: in this case, the relatively low dose of 600 micro g kg<sup>-1</sup> G4-CA was injected intraileally. The first intravenous injection of G4-CA (15 micro g kg<sup>-1</sup>) caused a significant mean peak increase above baseline in total acidity of 0.64 plus or minus 0.26 micro mol 15 min<sup>-1</sup> (P=0.017), while the second intravenous (i.v.) injection also caused significant increase of 0.72 plus or minus 0.26 micro mol 15 min<sup>-1</sup> (P=0.003) of 17 rats, ileal administration of G4-CA (600 micro g kg<sup>-1</sup>) resulted in a significant mean increase in gastric acid secretion of 1.84 plus or minus 1.49 micro mol (P=0.045) over the 3 hour collection period. When the G4-CA was infused into the jejunum, no increase in gastric acid secretion occurred. Furthermore, when this

jejunal infusion was then followed after 3 hours by ileal infusion of G4-CA, gastric acid secretion was strongly stimulated. In 5 rats, infusion of G4-CA (600 micro g kg-1 in 1.0 ml) into the jejunum caused a significant mean reduction in gastric acid levels. When G4-CA (600 micro g kg-1) was subsequently injected intra-ileally, the gastric acid levels were significantly increased by 1.63 plus or minus 0.31 micro mol. These results demonstrated the absorption of G4-CA with biological activity preserved. Furthermore, the absorption did not occur from the jejunum but was specific to the ileum: this indicated a requirement for bile salt facilitated transport. Experiments with gastrin decapeptide (G10) also showed that when G10-CA was infused intra-ileally on the same molar basis as G4-CA (1000 micro g kg-1 in 1.0 ml), there was considerable stimulation of gastric acid secretion. This confirmed that longer peptides were transportable across the wall of the ileum.

Dwg.0/0

FS CPI  
FA AB; GI; DCN  
MC CPI: B01-D02; B04-B04H; B04-C01A; B04-C01G; B04-C02; B04-E01; B04-G01;  
B04-H06; B04-H07; B04-J01; B04-L01

=> b home

FILE 'HOME' ENTERED AT 15:32:59 ON 23 JUN 2005

=>